Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | HLCS | P50747 | 2/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 2/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780724 | 1.00 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1CYP1A2HLCSS1PR2 | |
| SCHEMBL6036825 | 1.00 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1CYP1A2HLCSS1PR2 | |
| SCHEMBL10337476 | 1.00 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1CYP1A2HLCSS1PR2 | |
| SCHEMBL13082563 | 1.00 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1CYP1A2HLCSS1PR2 | |
| SCHEMBL9052248 | 0.98 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1CYP1A2HLCSS1PR2 | |
| SCHEMBL8443031 | 0.98 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1CYP1A2HLCSS1PR2 | |
| SCHEMBL5518415 | 0.98 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1CYP1A2HLCSS1PR2 | |
| SCHEMBL1439579 | 0.85 | — | — | |
| SCHEMBL2365737 | 0.85 | — | — | |
| SCHEMBL1439581 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 461 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217976-A1 | 6-(AMINO ACID)-MORPHINAN DERIVATIVES IN COMBINATION WITH PERMEATION ENHANCERS FOR USE AS AN ORALLY, RECTALLY, TRANSDERMALLY OR NASALLY ADMINISTERED MEDICAMENT | CHIRONWELLS GMBH (AT) | 2017-08-03 | — | — | US | claimed |
| EP-3116986-A1 | HAND SANITIZERS WITH IMPROVED AESTHETICS AND SKIN-CONDITIONING TO ENCOURAGE COMPLIANCE WITH HAND HYGIENE GUIDELINES | GOJO Industries, Inc. (US) | 2017-01-18 | — | — | EP | claimed |
| WO-2015139847-A1 | 6-(AMINO ACID)-MORPHINAN DERIVATIVES IN COMBINATION WITH PERMEATION ENHANCERS FOR USE AS AN ORALLY, RECTALLY, TRANSDERMALLY OR NASALLY ADMINISTERED MEDICAMENT | CHIRONWELLS GMBH (AT) | 2015-09-24 | — | — | WO | claimed |
| US-20150258003-A1 | HAND SANITIZERS WITH IMPROVED AESTHETICS AND SKIN-CONDITING TO ENCOURAGE COMPLIANCE WITH HAND HYGIENE GUIDELINES | SILVER POINT FINANCE, LLC, AS COLLATERAL AGENT | 2015-09-17 | — | — | US | claimed |
| WO-2015138926-A1 | HAND SANITIZERS WITH IMPROVED AESTHETICS AND SKIN-CONDITIONING TO ENCOURAGE COMPLIANCE WITH HAND HYGIENE GUIDELINES | GOJO INDUSTRIES, INC. (US) | 2015-09-17 | — | — | WO | claimed |
| EP-2916820-A1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | Rochal Industries, LLC (US) | 2015-09-16 | — | — | EP | claimed |
| EP-2836200-A2 | REVERSE THERMAL HYDROGEL PREPARATIONS FOR USE IN THE TREATMENT OF DISORDERS OF THE UROTHELIUM | Theracoat Ltd. (IL) | 2015-02-18 | — | — | EP | claimed |
| US-8852648-B2 | Delivery of biologically-active agents using volatile, hydrophobic solvents | ROCHAL INDUSTRIES, LLP (US) | 2014-10-07 | — | — | US | claimed |
| WO-2014074289-A1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | ROCHAL INDUSTRIES, LLP (US) | 2014-05-15 | — | — | WO | claimed |
| US-20140127320-A1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | ROCHAL INDUSTRIES, LLP (US) | 2014-05-08 | — | — | US | claimed |
| WO-2013153550-A2 | REVERSE THERMAL HYDROGEL PREPARATIONS FOR USE IN THE TREATMENT OF DISORDERS OF THE UROTHELIUM | THERACOAT LTD (IL) | 2013-10-17 | — | — | WO | claimed |
| US-20080124289-A1 | particularly 4-decyloxazolidin-2-one; for moisturizing skin without significant stickiness; biocompatibility | LVMH RECHERCHE (FR) | 2008-05-29 | — | — | US | claimed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | claimed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | claimed |
| US-6503478-B2 | Administering deuderated compound; spectrum analysis; applying electromagnetic waves, scanning | LIGHTOUCH MEDICAL, INC. | 2003-01-07 | — | — | US | claimed |
| US-20020041848-A1 | Administering deuderated compound; spectrum analysis; applying electromagnetic waves, scanning | AVALYRA INC. | 2002-04-11 | — | — | US | claimed |
| WO-2001051094-A1 | DIAGNOSTIC METHOD USING A DEUTERATED AGENT FOR IMAGING SPECIFIC TISSUE | LIGHTOUCH MEDICAL, INC. (US) | 2001-07-19 | — | — | WO | claimed |
| WO-1996033706-A1 | COMPOSITIONS AND METHODS FOR INDUCING DERMAL ANALGESIA | PHARMETRIX, INC. (US) | 1996-10-31 | — | — | WO | claimed |
| EP-0378657-B1 | OXAZOLIDINONE PENETRATION ENHANCING COMPOUNDS | RAJADHYAKSHA VITHAL J (US) | 1994-02-02 | — | — | EP | claimed |
| US-4960771-A | TRANSDERMAL DELIVERY OF THERAPEUTIC AGENTS; DRUGS, SUNSCREENS, INSECT REPELLENTS, COSMETICS | LVMH MOET HENNESSY LOUIS VUITTON, INC. | 1990-10-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124289-A1 | particularly 4-decyloxazolidin-2-one; for moisturizing skin without significant stickiness; biocompatibility | CUTA, TYR, DSC1 | ALDH1A1 530/4885L3MBTL1 2523/4885CYP1A2 1954/4885 |
| US-20020041848-A1 | Administering deuderated compound; spectrum analysis; applying electromagnetic waves, scanning | DSP, DVL3, DVL1 | ALDH1A1 681/4885L3MBTL1 1245/4885CYP1A2 92/4885 |
| US-20170217976-A1 | 6-(AMINO ACID)-MORPHINAN DERIVATIVES IN COMBINATION WITH PERMEATION ENHANCERS FOR USE AS AN ORALLY, RECTALLY, TRANSDERMALLY OR NASALLY ADMINISTERED MEDICAMENT | FABP2, SLC1A5, FABP6 | ALDH1A1 710/4885L3MBTL1 4571/4885CYP1A2 146/4885 |
| US-20150258003-A1 | HAND SANITIZERS WITH IMPROVED AESTHETICS AND SKIN-CONDITING TO ENCOURAGE COMPLIANCE WITH HAND HYGIENE GUIDELINES | CUTA, HAAO, HAO1 | ALDH1A1 12/4885L3MBTL1 3359/4885CYP1A2 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.